Efficacy and Safety of Chinese Herbal Formula Granules in Treating Chronic Kidney Disease Stage 3: A Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial
Table 2
Participant disposition.
Treatment group no. (%)
Control group no. (%)
Total no. (%)
Randomization
171 (100.00)
172 (100.00)
343 (100.00)
Safety analysis set (SS)
171 (100.00)
172 (100.00)
343 (100.00)
Full analysis set (FAS)
171 (100.00)
172 (100.00)
343 (100.00)
Dropouts during the study
21 (12.28)
22 (12.79)
43 (12.54)
Serious adverse events
2 (1.17)
0 (0.00)
2 (0.58)
Nonadherence to medication, e.g., discontinuation from study drug for more than 2 weeks without permission
